Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review.

ABSTRACT: Gliomas are tumors arising in the central nervous system, frequently associated with Class I mutations and BRAF fusions. These mutations are adverse prognostic factors in juvenile gliomas, leading to high rates of recurrence and poor response to current treatments. The blood-brain barrier and the heterogeneity of gliomas complicate the development of a single treatment strategy for all cases. This review aims to evaluate the efficacy and safety of combination therapies, particularly Dabrafenib and Trametinib, in pediatric gliomas with BRAF V600 mutations and discusses their potential in improving clinical outcomes. A review of recent clinical trials was conducted to assess the impact of targeted therapies, especially the combination of Dabrafenib and Trametinib, on glioma treatment outcome

SUBMITTER: Wahid MA 

PROVIDER: S-EPMC11630983 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature